ALMAZBY
DEAD

Serial Number

98064678

Owner

BRISTOL-MYERS SQUIBB COMPANY

Attorney

Marilyn F. Kelly

Filing Date

Jun 29, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ALMAZBY Trademark

Serial Number: 98064678

ALMAZBY is a trademark filed by BRISTOL-MYERS SQUIBB COMPANY on June 29, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

BRISTOL-MYERS SQUIBB COMPANY (4,799 trademarks)

NEW YORK, NY 10154

Entity Type: 03

Trademark Details

Filing Date

June 29, 2023

Registration Date

Not Registered

Published for Opposition

June 18, 2024

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; pharmaceutical preparations for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations; diagnostic agents, preparations and substances for medical purposes; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; radio-isotope markers for therapeutic or diagnostic use.

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 17, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 17, 2025 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 13, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 18, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jun 18, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 29, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 10, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 2, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 2, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 2, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 14, 2024 GNRN
NON-FINAL ACTION E-MAILED
Feb 14, 2024 GNRT
NON-FINAL ACTION WRITTEN
Feb 14, 2024 CNRT
ASSIGNED TO EXAMINER
Feb 7, 2024 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 2, 2023 TCCA
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 1, 2023 NWOS
NEW APPLICATION ENTERED
Jul 3, 2023 NWAP